Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by StockNews.com to “Buy”

StockNews.com downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a buy rating in a research report released on Monday morning.

Several other equities analysts have also commented on REGN. Royal Bank of Canada upped their price target on shares of Regeneron Pharmaceuticals from $1,232.00 to $1,240.00 and gave the stock an outperform rating in a research report on Friday, August 2nd. Argus lifted their target price on Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a buy rating in a report on Tuesday, June 25th. Evercore ISI began coverage on Regeneron Pharmaceuticals in a research report on Tuesday, May 14th. They set an outperform rating and a $1,150.00 price target for the company. Barclays boosted their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an overweight rating in a report on Friday, August 2nd. Finally, Wells Fargo & Company boosted their price objective on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an overweight rating in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of $1,108.45.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $1,179.37 on Monday. The stock has a fifty day moving average price of $1,109.49 and a 200 day moving average price of $1,017.47. Regeneron Pharmaceuticals has a 52 week low of $769.19 and a 52 week high of $1,211.20. The firm has a market capitalization of $130.01 billion, a P/E ratio of 34.84, a PEG ratio of 3.13 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $8.79 EPS. Equities research analysts anticipate that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Michael S. Brown sold 1,535 shares of the business’s stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total value of $1,596,400.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,437,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Regeneron Pharmaceuticals news, CEO Leonard S. Schleifer sold 9,064 shares of the business’s stock in a transaction on Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total transaction of $9,203,857.52. Following the completion of the sale, the chief executive officer now owns 55,134 shares in the company, valued at $55,984,717.62. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Michael S. Brown sold 1,535 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,437,280. The disclosure for this sale can be found here. Insiders have sold 20,625 shares of company stock valued at $22,298,963 over the last ninety days. Corporate insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 1.0% in the 1st quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after purchasing an additional 91,956 shares during the last quarter. Capital World Investors grew its holdings in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after buying an additional 23,146 shares in the last quarter. Capital International Investors increased its position in Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock valued at $3,011,640,000 after acquiring an additional 213,038 shares during the period. Putnam Investments LLC raised its stake in Regeneron Pharmaceuticals by 2.1% during the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after acquiring an additional 24,329 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $932,571,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.